Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease

[Farooqji]

a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.

inhibikase.com/news/press-r...

[Parkinsonjisung]

Is this a similar drug to nilotinib?

[park_bear in reply to Parkinsonjisung]

Do not know about the chemistry but they are apparently aiming for a similar effect. They reference some nilotinib research in their list of publications:

inhibikase.com/technology/s...

[Gratitude60]

Thanks for sharing!

[Hidden]

healthunlocked.com/cure-par...